Resonant Capital Advisors LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)

Resonant Capital Advisors LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,653 shares of the company's stock after acquiring an additional 2,366 shares during the quarter. Resonant Capital Advisors LLC's holdings in Johnson & Johnson were worth $4,752,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC lifted its position in shares of Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares during the last quarter. NewSquare Capital LLC boosted its holdings in shares of Johnson & Johnson by 145.8% in the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company's stock valued at $42,000 after buying an additional 172 shares in the last quarter. Assetmark Inc. grew its position in shares of Johnson & Johnson by 12.4% in the 4th quarter. Assetmark Inc. now owns 79,161 shares of the company's stock worth $11,448,000 after buying an additional 8,740 shares during the last quarter. Finally, Atria Investments Inc raised its stake in shares of Johnson & Johnson by 1.6% during the 4th quarter. Atria Investments Inc now owns 206,260 shares of the company's stock worth $29,829,000 after acquiring an additional 3,190 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $155.90 on Friday. The company has a 50 day simple moving average of $153.68 and a two-hundred day simple moving average of $154.03. The stock has a market cap of $375.11 billion, a price-to-earnings ratio of 17.34, a PEG ratio of 2.36 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. Johnson & Johnson's dividend payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.